IN2012DN01769A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01769A IN2012DN01769A IN1769DEN2012A IN2012DN01769A IN 2012DN01769 A IN2012DN01769 A IN 2012DN01769A IN 1769DEN2012 A IN1769DEN2012 A IN 1769DEN2012A IN 2012DN01769 A IN2012DN01769 A IN 2012DN01769A
- Authority
- IN
- India
- Prior art keywords
- antikine
- mip
- antibodies
- lß7ccl4
- ccl3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
Abstract
An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-lα/CCL3, MIP-lß7CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23801509P | 2009-08-28 | 2009-08-28 | |
PCT/US2010/047004 WO2011025962A1 (en) | 2009-08-28 | 2010-08-27 | Antikine antibodies that bind to multiple cc chemokines |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN01769A true IN2012DN01769A (en) | 2015-06-05 |
Family
ID=43628404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1769DEN2012 IN2012DN01769A (en) | 2009-08-28 | 2010-08-27 |
Country Status (18)
Country | Link |
---|---|
US (3) | US8313747B2 (en) |
EP (1) | EP2470671B1 (en) |
JP (2) | JP6109571B2 (en) |
KR (1) | KR101778813B1 (en) |
CN (1) | CN102782148B (en) |
AU (1) | AU2010286516B2 (en) |
BR (1) | BR112012004387A2 (en) |
CA (1) | CA2771781C (en) |
DK (1) | DK2470671T3 (en) |
ES (1) | ES2531561T3 (en) |
HR (1) | HRP20150162T1 (en) |
IN (1) | IN2012DN01769A (en) |
MX (1) | MX2012002427A (en) |
PL (1) | PL2470671T3 (en) |
PT (1) | PT2470671E (en) |
SI (1) | SI2470671T1 (en) |
SM (1) | SMT201500011B (en) |
WO (1) | WO2011025962A1 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2470671T3 (en) * | 2009-08-28 | 2015-05-29 | Regeneron Pharma | Antikine antibodies that bind to multiple cc chemokines |
CN103857421B (en) * | 2011-06-13 | 2017-09-22 | Tla指标免疫疗法公司 | The method for the treatment of cancer and the binding reagents used wherein |
WO2013033206A2 (en) * | 2011-08-29 | 2013-03-07 | University Of Rochester | Compositions and methods for inhibiting ccl3 |
WO2013036290A1 (en) * | 2011-09-09 | 2013-03-14 | Yale University | Compositions and methods for assessing and treating inflammatory diseases and disorders |
KR102134088B1 (en) | 2012-08-24 | 2020-07-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
TWI612059B (en) * | 2013-03-15 | 2018-01-21 | 美國禮來大藥廠 | Pan-elr+ cxc chemokine antibodies |
EP2999484B1 (en) * | 2013-05-23 | 2019-09-11 | Shire Human Genetic Therapies, Inc. | Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma |
JP6220222B2 (en) * | 2013-10-28 | 2017-10-25 | シスメックス株式会社 | Method, system and computer program product for assisting diagnosis of rheumatoid arthritis |
KR20230107382A (en) * | 2013-12-09 | 2023-07-14 | 알라코스 인크. | Anti-siglec-8 antibodies and methods of use thereof |
US10183996B2 (en) | 2014-02-28 | 2019-01-22 | Allakos Inc. | Methods and compositions for treating Siglec-8 associated diseases |
EP3114139B1 (en) * | 2014-03-04 | 2022-06-15 | Chemomab Ltd. | Anti eotaxin-2 antibodies that recognize additional ccr3-binding chemokines |
CN104198727A (en) * | 2014-08-22 | 2014-12-10 | 广西南宁隆吉维特生物科技有限公司 | Human serum CCL2 enzyme-linked immunosorbent assay kit as well as preparation and use methods thereof |
TWI576112B (en) * | 2014-10-24 | 2017-04-01 | 國立陽明大學 | Use of mip-1β inhibitor in protecting pancreatic islet and inhibiting the elevation of blood sugar level in diabetes mellitus |
EP3808775B1 (en) | 2014-12-09 | 2024-04-17 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
JP6846362B2 (en) | 2015-06-17 | 2021-03-24 | アラコス インコーポレイテッド | Methods and Compositions for Treating Fibrous Diseases |
US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
WO2018005519A2 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
WO2018106931A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
JP7122002B2 (en) | 2017-03-01 | 2022-08-19 | 国立大学法人北海道大学 | Method for producing a disease model non-human animal, disease model non-human animal, drug screening method using the animal, and disease risk determination method |
US11655306B2 (en) * | 2017-04-05 | 2023-05-23 | Korea Research Institute Of Bioscience And Biotechnology | NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same |
BR112019022912A2 (en) | 2017-05-05 | 2020-05-26 | Allakos Inc. | METHODS AND COMPOSITIONS TO TREAT ALLERGIC EYE DISEASES |
WO2019037067A1 (en) * | 2017-08-25 | 2019-02-28 | 法玛科技顾问股份有限公司 | APPLICATION OF MACROPHAGE INFLAMMATORY PROTEIN-1β (MIP-1β) INHIBITOR IN TREATMENT AND CONTROL OF ATHEROSCLEROSIS |
JP2020536557A (en) * | 2017-10-13 | 2020-12-17 | エー アンド ジー ファーマシューティカル,インコーポレイテッド | Monoclonal antibodies and conjugates to prostaglandin F2 receptor inhibitors, and their use |
WO2019133902A2 (en) * | 2017-12-28 | 2019-07-04 | Astute Medical, Inc. | Antibodies and assays for ccl14 |
US20200408777A1 (en) * | 2018-02-26 | 2020-12-31 | Cornell University | Quantitative biomarkers of ehv-1 susceptibility and protection |
CN112567244A (en) * | 2018-05-11 | 2021-03-26 | 哈尔西恩治疗公司 | Binding proteins and chimeric antigen receptor T cells targeting GASP-1 particles and uses thereof |
WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
CN110117329B (en) * | 2019-04-03 | 2020-12-08 | 河北浓孚雨生物科技有限公司 | Fusion polypeptides comprising chemokines and binding partners and uses thereof |
KR102489282B1 (en) * | 2019-07-02 | 2023-01-17 | 고려대학교 산학협력단 | Composition comprising C-C motif chemokine ligand 4, 5, 20, 21 for improving pregnancy |
EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
CN113893331A (en) * | 2020-07-06 | 2022-01-07 | 中国农业科学院特产研究所 | Product for inducing female deer to grow antler, preparation method thereof, method for inducing female deer to grow antler and application thereof |
US20230242623A1 (en) * | 2020-07-08 | 2023-08-03 | Georgia Tech Research Corporation | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection |
AU2021277712B2 (en) * | 2020-10-16 | 2023-05-25 | LaNova Medicines Limited | Anti-CCR8 monoclonal antibodies and uses thereof |
CN114990073A (en) * | 2022-05-27 | 2022-09-02 | 河南农业大学 | Monoclonal antibody for resisting porcine CCL2 protein, and preparation method and application thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
US7018627B1 (en) | 1995-06-07 | 2006-03-28 | Icos Corporation | Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof |
US6498015B1 (en) * | 1995-06-07 | 2002-12-24 | Icos Corporation | Methods of identifying agents that modulate the binding between MDC and an MDC receptor |
US6316420B1 (en) * | 1998-07-28 | 2001-11-13 | Technion Research And Development Foundation Ltd. | DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis |
US6420346B1 (en) | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
RU2339647C2 (en) | 2002-08-19 | 2008-11-27 | Астразенека Аб | Antibodies fighting monocyte chemoattractant protein-1 (mcp-1) and their application |
AU2003293096B9 (en) | 2002-11-27 | 2011-09-29 | Biogen Ma Inc. | Humanized antibodies against monocyte chemotactic proteins |
AU2005318173B2 (en) * | 2004-12-21 | 2011-05-12 | Merck Serono Sa | CC-chemokine antagonists |
ES2453592T3 (en) | 2007-08-02 | 2014-04-08 | Novimmune Sa | Anti-RANTES antibodies and methods of use thereof |
PL2470671T3 (en) * | 2009-08-28 | 2015-05-29 | Regeneron Pharma | Antikine antibodies that bind to multiple cc chemokines |
-
2010
- 2010-08-27 PL PL10812667T patent/PL2470671T3/en unknown
- 2010-08-27 EP EP20100812667 patent/EP2470671B1/en active Active
- 2010-08-27 BR BR112012004387A patent/BR112012004387A2/en active Search and Examination
- 2010-08-27 CA CA2771781A patent/CA2771781C/en active Active
- 2010-08-27 AU AU2010286516A patent/AU2010286516B2/en active Active
- 2010-08-27 IN IN1769DEN2012 patent/IN2012DN01769A/en unknown
- 2010-08-27 JP JP2012527033A patent/JP6109571B2/en active Active
- 2010-08-27 DK DK10812667T patent/DK2470671T3/en active
- 2010-08-27 WO PCT/US2010/047004 patent/WO2011025962A1/en active Application Filing
- 2010-08-27 SI SI201030901T patent/SI2470671T1/en unknown
- 2010-08-27 US US12/870,573 patent/US8313747B2/en active Active
- 2010-08-27 PT PT10812667T patent/PT2470671E/en unknown
- 2010-08-27 KR KR1020127007885A patent/KR101778813B1/en active IP Right Grant
- 2010-08-27 ES ES10812667.3T patent/ES2531561T3/en active Active
- 2010-08-27 CN CN201080048961.XA patent/CN102782148B/en not_active Expired - Fee Related
- 2010-08-27 MX MX2012002427A patent/MX2012002427A/en active IP Right Grant
-
2012
- 2012-10-22 US US13/657,120 patent/US9005617B2/en active Active
-
2015
- 2015-01-16 SM SM201500011T patent/SMT201500011B/en unknown
- 2015-02-10 HR HRP20150162TT patent/HRP20150162T1/en unknown
- 2015-02-24 US US14/630,112 patent/US20150166647A1/en not_active Abandoned
-
2016
- 2016-01-25 JP JP2016011829A patent/JP2016135783A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2771781A1 (en) | 2011-03-03 |
EP2470671B1 (en) | 2014-12-24 |
SMT201500011B (en) | 2015-03-05 |
EP2470671A1 (en) | 2012-07-04 |
KR20120091013A (en) | 2012-08-17 |
CN102782148B (en) | 2016-04-20 |
MX2012002427A (en) | 2012-08-03 |
KR101778813B1 (en) | 2017-09-14 |
US8313747B2 (en) | 2012-11-20 |
AU2010286516B2 (en) | 2016-10-06 |
CN102782148A (en) | 2012-11-14 |
US20110059107A1 (en) | 2011-03-10 |
DK2470671T3 (en) | 2015-02-09 |
JP6109571B2 (en) | 2017-04-05 |
HRP20150162T1 (en) | 2015-05-08 |
AU2010286516A2 (en) | 2012-06-14 |
JP2013503192A (en) | 2013-01-31 |
AU2010286516A1 (en) | 2012-03-08 |
PL2470671T3 (en) | 2015-05-29 |
US20130108640A1 (en) | 2013-05-02 |
CA2771781C (en) | 2019-01-15 |
JP2016135783A (en) | 2016-07-28 |
WO2011025962A1 (en) | 2011-03-03 |
EP2470671A4 (en) | 2013-04-03 |
RU2012111820A (en) | 2013-10-10 |
US20150166647A1 (en) | 2015-06-18 |
PT2470671E (en) | 2015-02-05 |
ES2531561T3 (en) | 2015-03-17 |
US9005617B2 (en) | 2015-04-14 |
SI2470671T1 (en) | 2015-04-30 |
BR112012004387A2 (en) | 2015-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN01769A (en) | ||
AR096713A1 (en) | PURIFICATION PROCESS FOR MONOCLONAL ANTIBODIES | |
AU2018200640B2 (en) | Humanization of rabbit antibodies using a universal antibody framework | |
CO2019001246A2 (en) | Anti-PD-1 antibodies, a production method and a method for its use | |
MX2010007935A (en) | Humanized anti-human nkg2a monoclonal antibody. | |
WO2011131746A3 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
WO2010039900A3 (en) | Non-human mammals for the production of chimeric antibodies | |
TN2014000107A1 (en) | Anti-aplhabetatcr antibody | |
DE602006006200D1 (en) | ANTIBODY AGAINST 25-HYDROXYVITAMINE D | |
MX2012000841A (en) | Optimizing the production of antibodies. | |
EA201992670A1 (en) | METHOD FOR OBTAINING BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | |
MX2011003855A (en) | Methods for producing antibodies from plasma cells. | |
MX2013003182A (en) | Purification of antibodies using simulated moving bed chromatography. | |
MX337684B (en) | Cross-reactive and bispecific anti-el 17a/f antibodies. | |
MX2009008608A (en) | Monoclonal anti-cxcl13 antibodies. | |
MX2012002458A (en) | Humanized anti-cdcp1 antibodies. | |
NZ594339A (en) | Anti-fgfr3 antibodies and methods using same | |
NZ706189A (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) | |
NZ588469A (en) | Antibodies to il-6 and their uses | |
MX337203B (en) | Novel jnk inhibitor molecules. | |
MX366112B (en) | Cell culture media and methods of antibody production. | |
MX2021014973A (en) | High affinity anti-cd3 antibodies, and methods for their generation and use. | |
EP2099812A4 (en) | Manufacturing method of tagatose using galactose isomerization of high yield | |
WO2013186630A3 (en) | Humanized antibodies to ca215 | |
WO2012122513A3 (en) | Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution |